Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.39 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.39 |
| ▸ | MMP7 | P09237 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | EZH2 | Q15910 | 3/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6303016 | 0.86 | KCNQ3 (0.48) | MMP2MMP9KCNQ3KCNQ2KCNE1 | |
| SCHEMBL6310134 | 0.85 | LOXL2 (0.41) | PPARGMMP2MMP9KCNQ3KCNQ2 | |
| SCHEMBL6304573 | 0.85 | MMP2 (0.47) | MMP2MMP9MMP7MMP13EZH2 | |
| SCHEMBL6310487 | 0.84 | GRM5 (0.43) | MMP2MMP9MMP7MMP13EZH2 | |
| SCHEMBL6311929 | 0.82 | MMP2 (0.55) | MMP2MMP9MMP7MMP13EZH2 | |
| SCHEMBL6310596 | 0.82 | CHRNB2 (0.41) | MMP2MMP9KCNQ3KCNQ2KCNE1 | |
| SCHEMBL6303691 | 0.82 | TAS1R3 (0.40) | TAS1R3TAS1R1TAS1R2PPARGMMP2 | |
| SCHEMBL7117240 | 0.82 | TAS1R3 (0.43) | TAS1R3TAS1R1TAS1R2MMP2MMP9 | |
| SCHEMBL6309581 | 0.82 | L3MBTL1 (0.42) | PPARGMMP2MMP9MMP7MMP13 | |
| SCHEMBL6305631 | 0.82 | EZH2 (0.41) | MMP2MMP9KCNQ3KCNQ2KCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-6852716-B2 | Substituted-aryl compounds for treatment of disease | PFIZER INC (US) | 2005-02-08 | — | — | US | disclosed |
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | NAT1, CYP7A1, CYP7B1 | TAS1R3 3558/4885TAS1R1 1839/4885TAS1R2 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.